P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience
نویسندگان
چکیده
منابع مشابه
OnabotulinumtoxinA for chronic migraine: a critical appraisal
Chronic migraine (CM) is a severe disabling condition with a few available evidence-based management options. OnabotulinumtoxinA (onaBoNTA) is approved for use in a number of disorders. Its benefits and potential use in migraine were observed incidentally while treating patients cosmetically for wrinkles. The mechanism of action of onaBoNTA in CM is not fully understood, but there is evidence t...
متن کاملOnabotulinumtoxinA for the treatment of chronic migraine.
Chronic migraine is a common primary headache disorder that actively afflicts as many as 1 in 50 individuals and accounts for a disproportionate share of the financial cost, pain, and emotional suffering produced by migraine generally. “Chronic migraine” implies that one has an established history of migraine, has been experiencing headaches on at least 15 days of each month for at least 3 cons...
متن کاملRefractory migraine in a headache clinic population
BACKGROUND Many migraineurs who seek care in headache clinics are refractory to treatment, despite advances in headache therapies. Epidemiology is poorly characterized, because diagnostic criteria for refractory migraine were not available until recently. We aimed to determine the frequency of refractory migraine in patients attended in the Headache Unit in a tertiary care center, according to ...
متن کاملOnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4-2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 201...
متن کاملOnabotulinumtoxinA (Botox) in chronic migraine with and without medication overuse
Chronic Migraine (CM) is one of the most disabling primary headache disorders affecting 2% of general population. CM is defined as headaches on >15 days per month for >3 months of which >8 days fulfill the criteria for migraine with or without aura or relieved by migrainespecific treatment [1].CM has an important economic and social impact compared with episodic migraine [2]. CM patients requir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Headache and Pain
سال: 2015
ISSN: 1129-2369,1129-2377
DOI: 10.1186/1129-2377-16-s1-a113